Abstract
Aim The aim of our work was to determine the utility of DNM1 as a biomarker for the diagnosis and prognosis of colon cancer (CC). Methods DNM1 expression variations in CC vs. normal tissues were investigated using The Cancer Genome Atlas (TCGA) database. The association of DNM1 expression levels with the clinicopathological variables in CC prognosis was investigated using logistic regression analyses. Independent prognostic factors for CC were evaluated using univariate and multivariate Cox regression analyses. The correlation between DNM1 expression and immune cell infiltration was estimated using single-sample Gene Set Enrichment Analysis (ssGSEA). Results DNM1 expression in CC tissues was significantly higher than that in normal tissues. High DNM1 expression was significantly correlated with M stage, N stage, perineural invasion and lymphatic invasion and predicted poor prognosis. The univariate analysis highlighted that DNM1 was an independent CC risk factor. Results of ssGSEA showed that DNM1 was linked to several cancer-related pathways, including the neuroactive ligand-receptor interaction, hypertrophic cardiomyopathy, ECM-receptor interaction, dilated cardiomyopathy, and calcium signaling pathway. Moreover, DNM1 expression was positively correlated with the level of infiltration by Neutrophils, Tregs, NK cells, and Macrophages. Conclusion DNM1 has a significant function and has diagnostic and prognostic potential for CC.
Highlights
It is estimated that colon cancer (CC) is among the leading cancers globally
In the univariate logistic regression analysis, the dynamin 1 (DNM1) level was found strongly correlated with clinicopathological features (Table 2), including N stage (OR = 2:092, 95% CI: 1.445-3.042, and p < 0:001), M stage (OR = 1:885, 95% CI: 1.103-3.287, and p = 0:022), pathologic stage (OR = 2:033, 95% CI: 1.402-2.960, and p < 0:001 ), perineural invasion (OR = 2:744, 95% CI: 1.376-5.670, and p = 0:005), and lymphatic invasion (OR = 2:018, 95% CI: 1.364-3.001, and p < 0:001)
These results suggest that high DNM1 expression predicts poor CC clinicopathological features
Summary
It is estimated that colon cancer (CC) is among the leading cancers globally. Annually, nearly 1.1 million new cases of CC and 551,000 CC deaths occur each year [1]. The prognosis of CC always depends on the cancer stage at diagnosis. CC is often detected at an advanced stage, after lymph node and distant metastases occurred, resulting in poor overall survival [3]. Due to high tumor heterogeneity at the single-cell level, local tumor biopsy results often fail to reflect the overall biology of the tumor and its disease process, which may contribute to the increased incidence of recurrence and metastases of CC [6, 7]. Serum biomarkers like carbohydrate CA19-9 and CEA are commonly used in cancer diagnosis and prognosis, their sensitivity and specificity are not high [8]. Several studies have pointed to the influence of the immune microenvironment on the development of colon cancer, suggesting that different types of immune cell infiltration may be used as new diagnostic and prognostic biomarkers [9, 10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
